OZ439: A winning network of partners
Prof. Jonathan Vennerstrom, Prof. Susan Charman & Dr Sergio Wittlin
The success of the OZ439 project can be attributed to the commitment, enthusiasm and range of scientific expertise of its partners from across the globe. Today, OZ439 is on track to potentially replace artemisinin and become a part of the much-needed one-dose cure for malaria.
Feeding the drug development pipeline through the discovery of novel chemistry
Dr Thierry Diagana, Novartis Institue for Tropical Diseases, Singapore
NITD is working in close collaboration with MMV to explore new drug discovery approaches for malaria. NITD609, if proven to be well tolerated, will be the first antimalarial not belonging to either the artemisinin or peroxide class to enter clinical efficacy studies in recent years.
Guiding the development of transmission-blocking medicines
Prof. Robert Sinden, Imperial College, London, UK
Current medicines mostly kill the malaria parasite at the blood stage, but to eradicate malaria, we need to stop the parasite being passed on to the next person via mosquitos. Imperial College London has been working with MMV to turn basic biology into knowledge to underpin the development of new antimalarials.
A weapon to counter resistance
Dr Jörg Möhrle, Head of Translational Medicine, MMV
OZ439 is a fully synthetic peroxide on track to provide not only a single-dose cure for malaria, but also a potential alternative to currently used artemisinin derivatives. Dr Jörg Möhrle explains this molecule.
A long-standing collaboration
Shin Poong Pharmaceutical, South Korea
MMV and Shin Poong have worked together since 1999 to develop Pyramax®. This new once daily, 3-day treatment for uncomplicated P. falciparum and blood stage P. vivax malaria in infants, children and adults is awaiting regulatory approval by the European Medicines Agency.
Treating patients with severe malaria
Dr Arjen Dondorp, Deputy Director and Head of Malaria Research,Mahidol–Oxford Tropical Medi-cine Research Unit, Bangkok, Thailand
MMV is using its R&D know-how, working with Guilin Pharmaceutical to achieve WHO prequalification for injectale artesunate, treatment for severe malaria. Dr Arjen Dondorp, speaks about treating patients with of severe malaria.
DHODH: Academic brain meets industrial muscle
Dr Meg Phillips, University of Texas Southwestern, USA
The enzyme DHODH is one the hottest malaria drug targets under investigation today. This project was awarded MMV’s 2010 Project of the Year in recognition of its impressive progress to rapidly bring these inhibitors towards clinical testing. Dr Meg Phillips speaks about the collaboration with MMV.
Overcoming the challenges of conducting clinical trials in India
Dr Neena Valecha, The National Institute of Malaria Research, India
NIMR is India’s premier malaria research institute, carrying out studies on drug resistance, and Phase II/ III trials of new drugs. Conducting clinical trials in India is a challenge but MMV and NIMR have had a successful partnership.
Delivering good, affordable drugs to those in need
Prof. Bruno Gryseels & Prof. Umberto D’Alessandro, ITM, Belgium
ITM provides postgraduate training for medical doctors and paramedics – a number of whom are headed for central Africa. Collaboration between MMV and ITM focuses on the development and trial of new antimalarials.